An Open-Label, Multicenter, Phase I/II Clinical Trial to Identify the Modufolin� Dose with Most Favorable Safety Prospect and Confirmed Ability to Mitigate High-Dose Methotrexate Induced Toxicity during Treatment of Osteosarcoma Patients
Read time: 1 mins
Last updated:9th Jul 2013
To characterize safety in terms of toxicity during HDMTX treatment and folate rescue therapy with either Modufolin� or Calcium Folinate. To identify the recommended dose of Modufolin� for further assessment.
|Study start date||2013-07-09|